ACADEMIC TRAINING: Doctor of Medicine from the Universidad de Málaga (1994). Graduate of Medicine from the University of Málaga (1982). RESIDENCY SPECIALITY: Specialist in Internal Medicine. Virgen de la Victoria University Hospital of Málaga (1986-1990). EXPERT: Haepatology. Infectious diseases. Autoimmune diseases. PROFESSIONAL EXPERIENCE: Associate Doctor of the Internal Medicine Services at the Virgen de la Victoria University Hospital of Málaga (1990). Associate Doctor of the Haepatology Unit of the Internal Medicine Services. Virgen de la Victoria University Hospital of Málaga (1990). PARTICIPATION IN PUBLICATIONS OF INTEREST: Gavilán JC, Ojeda G, Arnedo R, Puerta S. Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C. Eur J Intern Med. 2013 Jul 09. Salgado F, Gavilán JC, et al. Natural history and Incidence of the haepatocellular carcinoma in patients with chronic infection due to the hepatitis C virus. Revista Clínica Española. 200: 360-66; 2000. Salgado-Ordóñez F, Gavilán-Carrasco JC, Bermúdez-Recio FJ, et al. Absence of the inferior vena cava causing repeated deep venous thrombosis in an adult. A case report. Angiology. Angiology. 1998;49:951–6. Gavilán JC. Mortality in the severely obese. Obesity: medical treatment and surgical procedures. Málaga: Publication Services of the University of Málaga, 1997. ISBN: 84-7496-618-3. Gavilán JC. Hepatitis postransfusionales: Post-transfusional hepatitis: prospective study at the University Hospital of Málaga. Málaga: Publication Services of the University of Malaga, 1995. ISBN: 84-7496-433-4. OTHER ACHIEVEMENTS: Member of the Medical Board of the Clinical Hospital until 2012. Tutor responsible for the training of Residents and member of the Teaching Commission of the Clinical Hospital of Málaga (1991-2006). Member of the Faculty Board of the Faculty of Medicine of Málaga until 2012. Member of the Governing Board of the University of Málaga until 2006. Participation in multicentre clinical trials. Multicentre open study on the 12 week prediction of the response of Peginterferon alfa-2 (40 KD) in combination with Ribavirina on patients with chronic hepatitis C genotype I in the routine clinical practice. Protocol Code ML 16713 B. Financing entity: ROCHE FARMA S.A. 2002-2004. Participation in international multicentre clinical trials. Multicentre study of open use on interferon alfa-2 interferon (Ro 25-8310) in monotherapy and therapy combined with Ribavirina (Ro 20-9963) in patients with chronic hepatitis C (Clinical Trials in phase III). Protocol Code BV 16209. Financing entity: ROCHE FARMA S.A. (2001-2003). Member of the Social Security Health Research Fund’s (FISS) Research Group. Project title: Study of genetic alterations of interferons in viral hepatitis (project 92 / 0646). Financing entity: Social Security Health Research Fund (1992-1993). Member of the Technological Development and Research Group of the Andalusian Autonomous community (Group CTS 0277). Application of molecular genetic techniques to diagnose and monitor the treatment and epidemiology of infectious diseases. Financing entity: Directorate General for Universities and Research. 1996-1997-1998. Associate Clinical Professor of the Department of Medicine. Faculty of Medicine. University of Málaga since 1994.

 Hematology and Internal Medicine